Implications of oestrogen receptor status in primary breast carcinoma to the role of adjuvant chemotherapy in node-negative cases.
Recurrence occurred earlier in a small group of patients with node-negative breast carcinoma with oestrogen receptor (ER)-negative tumours, than in those in whom the tumour contained ER. The difference, indicative of an intrinsic advantage of an ER-positive tumour, was not seen following adjuvant chemotherapy. This finding could be explained on the basis of changes in the immunological balance between host and tumour brought about by treatment.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D012008:Recurrence
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen